2025
A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children
McGovern S, Johnson J, Luo D, Nguyen K, McAleer M, Paulino A, Grosshans D, Baxter P, Zaky W, Thall P, Mahajan A. A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children. International Journal Of Radiation Oncology • Biology • Physics 2025, 121: e13-e14. DOI: 10.1016/j.ijrobp.2024.11.049.Peer-Reviewed Original ResearchDose-volume constraintsSymptomatic brain necrosisRecurrent brain tumorsBrain tumorsBrain necrosisPrimary endpointDose constraintsProton therapyProspective studyRecurrent pediatric brain tumorsMedian overall survivalMedian prescription doseCourse of radiationResults Median ageTreated with radiationPediatric brain tumorsPrimary brain tumorProgression of diseaseBrain reirradiationDosimetric guidelinesDose escalationPrescription doseOverall survivalMedian intervalProspective trialsDynamic Contrast-enhanced MRI Processing Comparison for Distinguishing True Progression From Pseudoprogression in High-grade Glioma.
Amer A, Ansari S, Krayyem A, Kundu S, Khose S, Pokhylevych H, Calle S, Patel C, Yang Z, Liu H, Johnson J. Dynamic Contrast-enhanced MRI Processing Comparison for Distinguishing True Progression From Pseudoprogression in High-grade Glioma. Journal Of Computer Assisted Tomography 2025 PMID: 39876523, DOI: 10.1097/rct.0000000000001716.Peer-Reviewed Original ResearchHigh-grade gliomasBlood-brain barrierDCE-MRIPeak contrast enhancementQuantify BBB permeabilityTreatment-related changesFollow-up subjectsKtrans mapsTrue progressionTumor progressionClinical dataConventional MRIPseudoprogressionBBB permeabilityCombined pathologyKtransContrast enhancementT1 enhancementStandard processing methodologyStatistically significant resultsClinical data setsPathologyPatientsGliomaSSS techniqueRadiologist, trainee, and logistical factors impacting the timeliness of CTA head and neck reporting in stroke code activations.
Zaree O, Nguyen J, de Oliveira Santo I, Kertam A, Rahmani S, Johnson J, Tu L. Radiologist, trainee, and logistical factors impacting the timeliness of CTA head and neck reporting in stroke code activations. American Journal Of Neuroradiology 2025, ajnr.a8660. PMID: 39832953, DOI: 10.3174/ajnr.a8660.Peer-Reviewed Original ResearchStroke code activationAttending radiologistsTimeliness of reportingEmergency department settingRadiologist characteristicsCare settingsMultivariate regression modelImprove workflow efficiencyDepartment settingStroke codeModifiable factorsDescriptive statisticsSecondary analysisCoding activitiesReport factorsPatient ageObservational studyWorkflow efficiencyShift typeMedian TATMultivariate regressionInterquartile rangeRegression modelsCTA reportsLogistical factors
2024
The Impact of MRI-Based Advanced Neuroimaging on Neuro-Oncologists’ Clinical Decision-Making in Patients With Posttreatment High-Grade Glioma: A Prospective Survey
Samir A. Dagher, MD, Ho-Ling Liu, PhD, Burak Berksu Ozkara, MD, Susana Calle, MD, Diana Kaya, MD, Maria K. Gule, MD, Noah N. Chasen, MD, Dawid Schellingerhout, MD, Kim O. Learned, MD, Komal B. Shah, MD, Jason M. Johnson, MD, Jia Sun, PhD, Donald F. Schomer, MD, Vinodh A. Kumar, MD, Max Wintermark, MD, Nazanin K. Majd, MD, PhD, Joo Yeon Nam, MD, Melissa M. Chen, MD. The Impact of MRI-Based Advanced Neuroimaging on Neuro-Oncologists’ Clinical Decision-Making in Patients With Posttreatment High-Grade Glioma: A Prospective Survey. AJR 2024 Aug 14 [published online]. Accepted manuscript. doi:10.2214/AJR.24.31595Peer-Reviewed Original ResearchDifferential tractography and whole brain connectometry in primary motor area gliomas resection: A feasibility study.
Figueredo LF, MejÃa-Cordovez JA, Gomez-Amarillo DA, Hakim F, Pimienta-Redondo HD, Almeida JP, Kehayov I, Angelova P, Apostolov G, Luzzi S, Baldoncini M, Johnson JM, Ordóñez-Rubiano EG. Differential tractography and whole brain connectometry in primary motor area gliomas resection: A feasibility study. Clin Neurol Neurosurg 2024, 241: 108305. PMID: 38713964, DOI: 10.1016/j.clineuro.2024.108305.Peer-Reviewed Original ResearchTucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.
O'Brien B, Murthy R, Berry D, Singareeka Raghavendra A, Gule-Monroe M, Johnson J, Schwartz-Gomez J, Topletz-Erickson A, Lobbous M, Melisko M, Morikawa A, Ferguson S, de Groot J, Krop I, Valero V, Rimawi M, Wolff A, Tripathy D, Lin N, Stringer-Reasor E. Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results. Journal Of Clinical Oncology 2024, 42: 2018-2018. DOI: 10.1200/jco.2024.42.16_suppl.2018.Peer-Reviewed Original ResearchHER2+ breast cancerLeptomeningeal metastasesPatient-reported outcomesBreast cancerObjective responseClinical examCSF cytologyEvidence of clinically meaningful benefitHER2-targeted tyrosine kinase inhibitorsMedian time to CNS progressionMetastatic HER2+ breast cancerKarnofsky performance status >Treatment of leptomeningeal metastasesAbnormal CSF cytologyPerformance status >Targeted neurological deficitsMDASI-BTPhase 2 studyTyrosine kinase inhibitorsClinically meaningful benefitPre-specified timepointsPreliminary efficacy dataCNS progressionMedian OSCNS metastasesAdditive Value of Magnetic Resonance Simulation Before Chemoradiation in Evaluating Treatment Response and Pseudoprogression in High-Grade Gliomas
Yadav D, Upadhyay R, Kumar V, Chen M, Johnson J, Langshaw H, Curl B, Farhat M, Talpur W, Beckham T, Yeboa D, Swanson T, Ghia A, Li J, Chung C. Additive Value of Magnetic Resonance Simulation Before Chemoradiation in Evaluating Treatment Response and Pseudoprogression in High-Grade Gliomas. Practical Radiation Oncology 2024, 14: e449-e457. PMID: 38685448, DOI: 10.1016/j.prro.2024.04.009.Peer-Reviewed Original ResearchPseudo-progressionResponse assessmentInterobserver agreementImprove response assessmentPost-operative MRIFollow-up MRIFollow-up imagingEvaluate treatment responseHigh-grade gliomasIndependent blinded reviewIdentification of patientsClinical trial enrollmentWeeks of RTPartial response(PRStable disease(SDRT planningSalvage treatmentTumor responseEarly time pointsMedian intervalImprove patient outcomesTrue progressionProspective studyTreatment responseTumor progressionExpert-centered Evaluation of Deep Learning Algorithms for Brain Tumor Segmentation.
Hoebel K, Bridge C, Ahmed S, Akintola O, Chung C, Huang R, Johnson J, Kim A, Ly K, Chang K, Patel J, Pinho M, Batchelor T, Rosen B, Gerstner E, Kalpathy-Cramer J. Expert-centered Evaluation of Deep Learning Algorithms for Brain Tumor Segmentation. Radiology Artificial Intelligence 2024, 6: e220231. PMID: 38197800, PMCID: PMC10831514, DOI: 10.1148/ryai.220231.Peer-Reviewed Original ResearchConceptsBrain tumor segmentationDeep learning algorithmsSegmentation qualityLearning algorithmsTumor segmentationBrain tumor segmentation algorithmQuantitative quality metricsTumor segmentation algorithmClinical expert evaluationSegmentation performanceAlgorithm evaluationSegmentation algorithmQuality metricsDice scoreHausdorff distanceSegmentation casesAlgorithmExperimental resultsExpert evaluationQuality evaluationMetricsSurvey article
2023
Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Ferrarotto R, Nagarajan P, Maronge J, Johnson J, Rosenthal D, Myers J, Gross N. Outcomes of Treatment With Neoadjuvant Cemiplimab for Patients With Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngology - Head & Neck Surgery 2023, 149: 847-849. PMID: 37535378, PMCID: PMC10401391, DOI: 10.1001/jamaoto.2023.1729.Peer-Reviewed Original ResearchAdvances in the Radiological Evaluation of and Theranostics for Glioblastoma
Hooper G, Ansari S, Johnson J, Ginat D. Advances in the Radiological Evaluation of and Theranostics for Glioblastoma. Cancers 2023, 15: 4162. PMID: 37627190, PMCID: PMC10453051, DOI: 10.3390/cancers15164162.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPrognostic factors for pediatric, adolescent, and young adult patients with non-DIPG grade 4 gliomas: a contemporary pooled institutional experience
Matsui J, Allen P, Perlow H, Johnson J, Paulino A, McAleer M, Fouladi M, Grosshans D, Ghia A, Li J, Zaky W, Chintagumpala M, Palmer J, McGovern S. Prognostic factors for pediatric, adolescent, and young adult patients with non-DIPG grade 4 gliomas: a contemporary pooled institutional experience. Journal Of Neuro-Oncology 2023, 163: 717-726. PMID: 37440097, DOI: 10.1007/s11060-023-04386-4.Peer-Reviewed Original ResearchMultidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation.
Chelariu-Raicu A, Piha-Paul SA, Chavez-MacGregor M, Johnson J, Sawaya R, McAleer MF, Nguyen A, Hartnett A, Tsimberidou AM, Meric-Bernstam F, Dumbrava EE. Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation. J Immunother Precis Oncol 2023, 6: 158-161. PMID: 37637237, DOI: 10.36401/JIPO-22-33.Peer-Reviewed Case Reports and Technical NotesImmuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results.
Ferrarotto R, Johnson F, Hutcheson K, Sui D, Johnson J, Ebersole B, Mott F, Lewis C, Bonini F, Hoff C, Mitani Y, Cortez M, Bell D, El-Naggar A, Gunn G, Fuller C, Myers J, Lee J, Rosenthal D, Diaz E. Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results. Journal Of Clinical Oncology 2023, 41: 6008-6008. DOI: 10.1200/jco.2023.41.16_suppl.6008.Peer-Reviewed Original ResearchTreatment-related adverse eventsPathologic complete responseLarynx squamous cell carcinomaCo-primary endpointsEarly recurrenceCommon treatment-related adverse eventsStage IIDisease control rateLaryngeal preservation rateSolitary lung metastasisRelapse-free survivalSquamous cell carcinomaLoss of insuranceSingle treatment modalityAUC 6Eligible ptsEvaluable patientsImmuno-chemotherapyLarynx biopsiesDefinitive radiotherapyEfficacy endpointPrimary endpointRECIST 1.1Secondary endpointsAdverse eventsIntracranial mesenchymal tumor, FET::CREB fusion-positive in the lateral ventricle.
Ozkizilkaya HI, Johnson JM, O'Brien BJ, McCutcheon IE, Prabhu SS, Ghia AJ, Fuller GN, Huse JT, Ballester LY. Intracranial mesenchymal tumor, FET::CREB fusion-positive in the lateral ventricle. Neurooncol Adv 2023, 5: vdad026. PMID: 37051329, DOI: 10.1093/noajnl/vdad026.Peer-Reviewed Case Reports and Technical NotesMulti-Specialty Expert Physician Identification of Extranodal Extension in Computed Tomography Scans of Oropharyngeal Cancer Patients: Prospective Blinded Human Inter-Observer Performance Evaluation.
Multidisciplinary OPC ENE Group. Multi-Specialty Expert Physician Identification of Extranodal Extension in Computed Tomography Scans of Oropharyngeal Cancer Patients: Prospective Blinded Human Inter-Observer Performance Evaluation. MedRxiv 2023 PMID: 36865096, DOI: 10.1101/2023.02.25.23286432.Peer-Reviewed Original ResearchPostnatal Surgical Correction of Myelomeningoceles: Preoperative and Intraoperative Risk Factors Associated with Postoperative Neurologic Outcomes.
Acosta-Medina E, Zorro-GuÃo OF, Abdala-Vargas NJ, Jacomussi-Alzate L, Figueredo LF, Johnson JM, Patiño-Gómez JG, Ordóñez-Rubiano EG. Postnatal Surgical Correction of Myelomeningoceles: Preoperative and Intraoperative Risk Factors Associated with Postoperative Neurologic Outcomes. World Neurosurg 2023, 170: e629-e638. PMID: 36410703, DOI: 10.1016/j.wneu.2022.11.079.Peer-Reviewed Original Research
2022
A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Adults
McGovern S, Luo D, Johnson J, Nguyen K, Li J, McAleer M, Yeboa D, Grosshans D, Ghia A, Chung C, Bishop A, Song J, Thall P, Brown P, Mahajan A. A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Adults. Practical Radiation Oncology 2022, 13: 231-238. PMID: 36596356, DOI: 10.1016/j.prro.2022.12.006.Peer-Reviewed Original ResearchOral Contraceptives (Estrogen and Progestin)
Kimberly Kallianos, Daniel Thomas Ginat, Jason M Johnson. Oral Contraceptives (Estrogen and Progestin). In: Neuroimaging Pharmacopoeia (2022). Springer International Publishing, 427-432, 2022.ChaptersRecombinant Human Bone Morphogenetic Protein
Marianne S Reed, Jason M Johnson, Daniel Thomas Ginat. Recombinant Human Bone Morphogenetic Protein. In: Neuroimaging Pharmacopoeia (2022). Springer International Publishing, 415-417, 2022.ChaptersSynthetic Corticosteroids
Jason M Johnson, Yi Li, Daniel Thomas Ginat. Synthetic Corticosteroids. In: Neuroimaging Pharmacopoeia (2022). Springer International Publishing, 381-389, 2022.Chapters
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply